Clinical Trials

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma


Study ID
Eisai E7080-G000-307

NCT Number
NCT02811861 (Click on the NCT number for more information about the trial)

Research Study Number
2016-0627

Principle Investigator
Dr. Robert Alter

Phase
III

Sponsor
Eisai


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now